Gd-DOTA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413907

CAS#: 92923-44-9

Description: Gd-DOTA is a potential MRI contrast agent


Chemical Structure

img
Gd-DOTA
CAS# 92923-44-9

Theoretical Analysis

MedKoo Cat#: 413907
Name: Gd-DOTA
CAS#: 92923-44-9
Chemical Formula: C16H28GdN4NaO8
Exact Mass: 585.10
Molecular Weight: 584.660
Elemental Analysis: C, 32.87; H, 4.83; Gd, 26.90; N, 9.58; Na, 3.93; O, 21.89

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Gd-DOTA; Gadolinium dota; Dotarem

IUPAC/Chemical Name: Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate

InChi Key: DFTYBKPBYWCVAV-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H28N4O8.Gd.Na/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26;;/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28);;/q;-1;+1

SMILES Code: O=C1CN23CCN45CCN67CCN8(CC([O-][Gd+3]3468([O-]C(C5)=O)([O-]1)[O-]C(C7)=O)=O)CC2.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 584.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gulino P, Bianchi A, Diciotti S, Scionti A, Sali L, Papadopulos P, Mascalchi M. The switch from Gd-DTPA to Gd-DOTA is not associated with decrease of the T1 signal intensity of the pallidus and dentate in a pediatric population. Acta Radiol. 2021 Mar;62(3):368-376. doi: 10.1177/0284185120927920. Epub 2020 Jun 12. PMID: 32529894.

2: Forero Ramirez LM, Gobin E, Aid-Launais R, Journe C, Moraes FC, Picton L, Le Cerf D, Letourneur D, Chauvierre C, Chaubet F. Gd(DOTA)-grafted submicronic polysaccharide-based particles functionalized with fucoidan as potential MR contrast agent able to target human activated platelets. Carbohydr Polym. 2020 Oct 1;245:116457. doi: 10.1016/j.carbpol.2020.116457. Epub 2020 May 25. PMID: 32718599.

3: Wybranski C, Siedek F, Damm R, Gazis A, Wenzel O, Haneder S, Persigehl T, Steinhauser S, Pech M, Fischbach F, Fischbach K. Respiratory motion artefacts in Gd-EOB-DTPA (Primovist/Eovist) and Gd-DOTA (Dotarem)-enhanced dynamic phase liver MRI after intensified and standard pre-scan patient preparation: A bi- institutional analysis. PLoS One. 2020 Mar 20;15(3):e0230024. doi: 10.1371/journal.pone.0230024. PMID: 32196535; PMCID: PMC7083299.

4: Wang H, Sebrié C, Judé S, Maurin A, Rétif S, Le Mée M, Julea F, Dubuisson RM, Willoquet G, Bouazizi K, Darrasse L, Guillot G, Maître X, de Rochefort L. Quantitative Gd-DOTA-based aerosol deposition mapping in the lungs of asthmatic rats using 3D UTE-MRI. NMR Biomed. 2018 Dec;31(12):e4013. doi: 10.1002/nbm.4013. Epub 2018 Oct 11. PMID: 30307075.

5: Lee H, Mortensen K, Sanggaard S, Koch P, Brunner H, Quistorff B, Nedergaard M, Benveniste H. Quantitative Gd-DOTA uptake from cerebrospinal fluid into rat brain using 3D VFA-SPGR at 9.4T. Magn Reson Med. 2018 Mar;79(3):1568-1578. doi: 10.1002/mrm.26779. Epub 2017 Jun 19. PMID: 28627037; PMCID: PMC5736474.

6: Demine S, Balhuizen A, Debaille V, Joosten L, Fereau M, Chilla SNM, Millard I, Scharfmann R, Egrise D, Goldman S, Marchetti P, Gotthardt M, Laurent S, Burtea C, Eizirik DL. Imaging of Human Insulin Secreting Cells with Gd-DOTA-P88, a Paramagnetic Contrast Agent Targeting the Beta Cell Biomarker FXYD2γa. Molecules. 2018 Aug 21;23(9):2100. doi: 10.3390/molecules23092100. PMID: 30134599; PMCID: PMC6225257.

7: Zhang P, Zhang Y, Li B, Zhang H, Lin H, Deng Z, Tan B. Cell-assembled nanoclusters of MSC-targeting Gd-DOTA-peptide as a T2 contrast agent for MRI cell tracking. J Pept Sci. 2018 Jun;24(4-5):e3077. doi: 10.1002/psc.3077. Epub 2018 Mar 27. PMID: 29582508.

8: Colosimo C, Knopp MV, Barreau X, Gérardin E, Kirchin MA, Guézénoc F, Lodemann KP. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology. 2004 Aug;46(8):655-65. doi: 10.1007/s00234-003-1128-4. Epub 2004 Jun 15. PMID: 15205859.

9: Bousquet JC, Saini S, Stark DD, Hahn PF, Nigam M, Wittenberg J, Ferrucci JT Jr. Gd-DOTA: characterization of a new paramagnetic complex. Radiology. 1988 Mar;166(3):693-8. doi: 10.1148/radiology.166.3.3340763. PMID: 3340763.

10: Mortensen KN, Sanggaard S, Mestre H, Lee H, Kostrikov S, Xavier ALR, Gjedde A, Benveniste H, Nedergaard M. Impaired Glymphatic Transport in Spontaneously Hypertensive Rats. J Neurosci. 2019 Aug 7;39(32):6365-6377. doi: 10.1523/JNEUROSCI.1974-18.2019. Epub 2019 Jun 17. PMID: 31209176; PMCID: PMC6687896.